{"gene":"ETS2","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1996,"finding":"Ras signaling induces phosphorylation of a conserved threonine residue (T72 in ETS2, T38 in ETS1) that is required for Ras-mediated transcriptional superactivation of Ets-responsive reporters containing Ets-AP-1 binding sites.","method":"Phosphoamino acid analysis of radiolabeled ETS2, site-directed mutagenesis (T72A), transient transfection reporter assays in NIH 3T3 and RAW264 cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro phosphorylation confirmed by phosphoamino acid analysis plus mutagenesis abolishing activity, replicated across multiple labs","pmids":["8552081"],"is_preprint":false},{"year":1988,"finding":"ETS2 protein is a short-lived (half-life ~20 min) nuclear phosphoprotein; activation of protein kinase C (PKC) by TPA or diacylglycerol stabilizes ETS2 protein (half-life >2 h) through a post-translational mechanism without significantly increasing mRNA levels.","method":"Pulse-chase metabolic labeling, cycloheximide chase, PKC inhibitor H7 treatment, subcellular fractionation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal biochemical methods in a single study demonstrating PKC-dependent protein stabilization","pmids":["3062367"],"is_preprint":false},{"year":1990,"finding":"ETS2 (and ETS1) function as sequence-specific transcriptional activators by binding to GGAA-containing Ets-binding sites in the HTLV-1 LTR enhancer region; nuclear localization is required for transactivation activity.","method":"Transient co-transfection CAT reporter assays, gel-shift DNA-binding assay, competition experiments with oligonucleotides, nuclear localization mutant analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 — DNA-binding and transactivation confirmed by multiple orthogonal methods","pmids":["2209540"],"is_preprint":false},{"year":1990,"finding":"ETS2 expression is required for hormone-induced meiotic maturation (germinal vesicle breakdown) in Xenopus oocytes, as antisense oligonucleotide-mediated degradation of ets-2 mRNA blocks this process.","method":"Antisense oligonucleotide injection into Xenopus oocytes, hormone-induced maturation assay","journal":"Science","confidence":"Medium","confidence_rationale":"Tier 2 — clean loss-of-function with defined cellular phenotype; Xenopus ortholog consistent with mammalian ETS2","pmids":["2255913"],"is_preprint":false},{"year":1990,"finding":"ETS2 expression is rapidly and transiently induced in macrophages in response to CSF (cMGF), LPS, and PKC activators; PKC down-regulation blunts cMGF-induced ETS2 expression, implicating PKC in the signaling pathway.","method":"Northern blot, protein analysis, PKC inhibition/down-regulation experiments in chicken bone marrow macrophages, human monocytes, and mouse peritoneal macrophages","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 — multiple cell types and pharmacological inhibition with consistent results","pmids":["2186967"],"is_preprint":false},{"year":1990,"finding":"ETS2 phosphorylation is induced within 5 min by T-cell antigen receptor-CD3 complex activation in Jurkat cells, mediated through calcium (mimicked by Ca2+ ionophores), detected as a mobility shift from 54 to 56 kDa.","method":"32P metabolic labeling, SDS-PAGE mobility shift, antibody stimulation of TCR-CD3, Ca2+ ionophore treatment","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct biochemical detection with pharmacological dissection of pathway","pmids":["2137553"],"is_preprint":false},{"year":1992,"finding":"The carboxyl-terminal domain of ETS2 (and ETS1) acts as an inhibitory domain that reduces DNA binding affinity; deletion of as few as 16 C-terminal amino acids increases DNA binding 20–50-fold, and this domain acts directly on DNA binding rather than through homodimerization.","method":"Gel-shift binding assay, deletion mutagenesis, in vitro cotranslation experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis defining the inhibitory domain","pmids":["1409581"],"is_preprint":false},{"year":1992,"finding":"The ETS2 DNA-binding domain acts as a dominant-negative to suppress Ras-responsive enhancer activity and inhibit CSF-1-dependent colony formation; ectopic ETS2 rescues the c-myc response that is impaired when Ets-LacZ is expressed, placing ETS2 upstream of c-Myc in the CSF-1/Ras mitogenic signaling cascade.","method":"Stable expression of Ets-LacZ fusion in NIH 3T3 cells, colony formation assays, Northern blot analysis of c-ets-2, c-jun, c-fos, c-myc; rescue by c-myc overexpression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — epistasis established by dominant-negative and rescue experiments with defined phenotypic readouts","pmids":["1448070"],"is_preprint":false},{"year":1998,"finding":"MAP kinases p42/p44 (ERK1/2) directly phosphorylate ETS2 at T72 in response to CSF-1/c-fms signaling, leading to persistent ETS2 phosphorylation and activation of the uPA gene target; the RAF/MAP kinase pathway is specifically required for both ETS2 expression and post-translational activation.","method":"Phospho-specific antibody (anti-pT72), in vitro kinase assay with recombinant ETS2, MEK inhibitor PD98059, immune depletion of MAP kinases, conditional Raf expression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay combined with phospho-specific antibody detection and pharmacological inhibition","pmids":["9710599"],"is_preprint":false},{"year":1998,"finding":"ETS2 (and ETS1) transactivate the uPA and MMP-9 promoters in response to EGF through composite Ets-AP-1 binding sites; mutation of the conserved threonine (T75 of chicken ETS2, equivalent to T72) abolishes this EGF-dependent cooperation, linking EGF→Ras/ERK→ETS2 to invasion-associated protease expression.","method":"Reporter transfection assays, site-directed mutagenesis of Ets and AP-1 binding sites and T75 phosphorylation site, ETS2 expression vectors","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 1 — promoter mutagenesis and phosphorylation site mutation with functional readouts","pmids":["9639404"],"is_preprint":false},{"year":1998,"finding":"Targeted deletion of the ETS2 DNA-binding domain causes embryonic lethality due to defective trophoblast/extraembryonic tissue function, with failure of ectoplacental cone proliferation and deficient MMP-9 expression; rescued Ets2-deficient fibroblasts fail to induce MMP-13 and MMP-3 in response to FGF, and ectopic ETS2 restores this MMP expression.","method":"Gene targeting/knockout mice, tetraploid aggregation rescue, Northern blot for MMPs, ectopic ETS2 re-expression in knockout fibroblasts","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined phenotype, rescue by re-expression, replicated across multiple cell types and conditions","pmids":["9573048"],"is_preprint":false},{"year":1999,"finding":"ETS2 physically interacts with the coactivators p300 and CBP in vivo; two independent regions of p300/CBP (aa 328–596 and aa 1678–2370) directly bind the ETS2 transactivation domain in vitro and in vivo, enabling coactivator recruitment to the stromelysin promoter.","method":"Co-immunoprecipitation from cells, GST-pulldown with purified proteins, reporter transactivation assays, domain-mapping deletion analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct in vitro binding with purified proteins confirmed by reciprocal co-IP and functional reporter assays","pmids":["10358095"],"is_preprint":false},{"year":2001,"finding":"CDK10, a CDC2-related kinase, physically interacts with the N-terminus (Pointed domain) of ETS2 and inhibits ETS2 transactivation activity; the interaction is ETS2-specific (CDK10 does not bind ETS1 in yeast two-hybrid) and requires an intact Pointed domain.","method":"Yeast two-hybrid, in vitro binding (GST-pulldown), co-immunoprecipitation from mammalian cells, transactivation reporter assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — yeast two-hybrid plus in vitro and in vivo binding with functional consequence","pmids":["11313931"],"is_preprint":false},{"year":2003,"finding":"ETS2 interacts with components of the mammalian SWI/SNF chromatin remodeling complex (BRG-1, BAF57/p50, INI1) through its Pointed domain to form a repressor complex; BRG-1 directly binds the ETS2 Pointed domain in a phosphorylation-dependent manner, and the ETS2/BRG-1 complex represses the BRCA1 promoter.","method":"Biochemical affinity purification of Pointed-domain-interacting proteins, co-immunoprecipitation, in vitro pulldown, reporter repression assays, conditional ETS2 overexpression in MCF-7","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — unbiased biochemical screen followed by direct binding, co-IP, and functional gene repression assays","pmids":["12637547"],"is_preprint":false},{"year":2004,"finding":"ERK1/2-mediated phosphorylation of ETS2 (and ETS1) at the conserved N-terminal threonine (T72) enhances transactivation by promoting preferential recruitment of the coactivators CBP and p300; this interaction requires both the phosphoacceptor site and the Pointed domain, and was identified by unbiased affinity chromatography of HeLa nuclear extracts.","method":"Affinity chromatography of HeLa nuclear extracts using phospho- vs. mock-ETS2 as ligand, direct binding with purified proteins, co-immunoprecipitation from cells, MEK1-stimulated reporter assays, CBP co-expression experiments","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — unbiased biochemical screen with reconstituted direct binding and in vivo functional validation","pmids":["15572696"],"is_preprint":false},{"year":2003,"finding":"ETS2 overexpression induces apoptosis through the p53 pathway; genetic rescue by p53 knockout (crossing ETS2 transgenic mice with p53-/- mice) abolishes the thymic apoptosis phenotype, placing ETS2 upstream of p53-dependent apoptosis.","method":"ETS2 transgenic mice, p53-/- crossing/genetic rescue, p53 and downstream factor expression analysis, HeLa transfection with p53 and ETS2","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo with functional rescue and orthologous cell line data","pmids":["12554679"],"is_preprint":false},{"year":2001,"finding":"ETS2 and PU.1 synergistically transactivate the Bcl-xL promoter in macrophages; this synergy depends on the transactivation domains of both proteins and is specific (ETS1 does not substitute for ETS2), and overexpression of both factors increases macrophage survival upon CSF-1 withdrawal.","method":"Reporter transactivation assays, domain deletion analysis, retroviral overexpression in bone marrow-derived macrophages, CSF-1 withdrawal survival assays, Bax-induced apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including functional cellular rescue and promoter mechanistic analysis","pmids":["11278399"],"is_preprint":false},{"year":2002,"finding":"PTEN suppresses insulin-stimulated ETS2 phosphorylation (at the T72 MAP kinase site) through inhibition of ERK/MAP kinase signaling independently of PI3K/Akt, and this functional suppression is dependent on PTEN phosphatase activity; phosphatase-dead PTEN fails to block ETS2 phosphorylation or uPA RRE activation.","method":"Phospho-specific ETS2 antibody (anti-pT72), MEK inhibitor vs PI3K inhibitor treatment, PTEN overexpression, uPA RRE reporter assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — pharmacological dissection of pathways with phospho-specific readout and functional reporter confirmation","pmids":["12095911"],"is_preprint":false},{"year":2003,"finding":"MAP kinase phosphorylation of ETS2 at T72 is required for mammary tumor progression; knock-in mice with T72A mutation (Ets2A72) develop normally but show restricted mammary tumor growth, with decreased stromal MMP-9 and MMP-3 expression in macrophages, identifying ETS2 pT72 as acting in tumor stroma.","method":"Gene-targeted knock-in mice (T72A point mutation), mammary tumor models (polyoma middle T, Neu, Neu+VEGF), tumor transplantation into fat pads, macrophage MMP expression analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — precise phosphorylation site knock-in with multiple tumor models and defined molecular readouts","pmids":["14612405"],"is_preprint":false},{"year":2004,"finding":"Constitutive phosphorylation of ETS2 at T72 is required for persistent inflammatory macrophage responses in the motheaten viable model; Ets2A72 allele (T72A knock-in) reduces inflammatory gene expression (TNF-α, CCL3, MMP-9, integrin αM, Bcl-X), increases macrophage apoptosis, and extends lifespan of me-v mice.","method":"Genetic double-mutant mice (Ets2A72 × Hcph me-v), alveolar macrophage gene expression analysis, LPS stimulation of bone marrow-derived macrophages, macrophage apoptosis assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic epistasis with multiple molecular readouts and defined phosphorylation site","pmids":["15240733"],"is_preprint":false},{"year":2005,"finding":"ETS2 directly activates Bcl-xL transcription in osteoclasts; TNF stimulates ETS2 expression in osteoclasts, which in turn upregulates Bcl-xL, protecting osteoclasts from bisphosphonate-induced apoptosis; dominant-negative ETS2 blocks this TNF-protective effect.","method":"Retrovirus-mediated ETS2 overexpression in osteoclasts, dominant-negative ETS2 construct, in vitro osteoclast survival assay, Bcl-xL mRNA measurement, TNF-Tg mouse model","journal":"Arthritis and rheumatism","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function with defined molecular target in primary osteoclasts","pmids":["16142752"],"is_preprint":false},{"year":2007,"finding":"ETS2 is required for trophoblast stem (TS) cell self-renewal; conditional inactivation of ETS2 reduces TS cell growth and promotes differentiation; a direct target in TS cells is CDX2, a master regulator of TS cell state, identified by chromatin analysis.","method":"Conditional Ets2 knockout via targeted allele, gene expression analysis, identification of CDX2 as direct ETS2 target","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with defined cellular phenotype and direct target identification","pmids":["17977525"],"is_preprint":false},{"year":2012,"finding":"Mutant p53 (gain-of-function) interacts with ETS2 to regulate gene expression through ETS-binding sites in promoters; ETS2 mediates mutant p53 binding to EBS motifs and together they activate TDP2 transcription, contributing to etoposide resistance.","method":"ChIP-seq (genome-wide mutant p53 binding), reporter assays with EBS motifs, co-immunoprecipitation, TDP2 knockdown sensitization assays, gene expression analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — genome-wide binding analysis, direct interaction, and functional drug sensitivity assays","pmids":["22508727"],"is_preprint":false},{"year":2012,"finding":"Co-expression of ETS2 and MESP1 transcription factors reprograms human dermal fibroblasts into cardiac progenitors expressing KDR+ cardiac mesoderm marker, core cardiac transcription factors, Ca2+ transients, and sarcomeres; neither factor alone is sufficient.","method":"Lentivirus-mediated forced expression, marker expression analysis (KDR, cardiac TFs), Ca2+ imaging, sarcomere detection, embryonic stem cell cardiopoiesis assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal functional readouts with defined transcription factor combination","pmids":["22826236"],"is_preprint":false},{"year":2013,"finding":"ETS2 directly binds to the promoters of miR-155 in macrophages in response to LPS; ETS2-deficient mice show decreased miR-155 induction by LPS; IL-10 inhibits ETS2 induction, reducing its activity on the miR-155 promoter.","method":"Promoter truncation/mutational analysis, ChIP assay, ETS2-deficient mice, LPS stimulation, IL-10 treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — direct promoter binding by ChIP confirmed by in vivo mouse model and promoter mutagenesis","pmids":["24362029"],"is_preprint":false},{"year":2013,"finding":"ETS2 suppresses MET phosphorylation and MET-dependent cell invasion in lung cancer cells; ETS2 knockdown augments HGF-induced MET phosphorylation and invasion, placing ETS2 as a negative regulator of the HGF/MET pathway.","method":"RNAi knockdown, MET phosphorylation Western blot, invasion assays, MET knockdown epistasis experiment, microarray pathway analysis","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined molecular and cellular readouts and epistasis experiment","pmids":["23659968"],"is_preprint":false},{"year":2013,"finding":"HGF-MET signaling leads to accumulation of ETS2, which interacts with the MLL histone methyltransferase complex to transactivate MMP1 and MMP3 promoters; ChIP assays show increased occupancy of the MLL-ETS2 complex and increased H3K4 trimethylation at these promoters upon HGF-MET activation.","method":"Co-immunoprecipitation of MLL-ETS2 complex, ChIP assay for complex occupancy and H3K4me3, HGF treatment of hepatocellular carcinoma cell lines, MLL knockout mouse phenotypic analysis","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — direct complex identification, ChIP for epigenetic mark, and in vivo genetic model","pmids":["23934123"],"is_preprint":false},{"year":2014,"finding":"ETS2 in macrophages regulates the expression of miR-21, miR-29a, miR-142-3p, and miR-223 downstream of CSF1 signaling; CSF1-ETS2-induced microRNAs promote M2 reprogramming, angiogenesis, and metastatic tumor growth by targeting anti-angiogenic genes.","method":"Loss-of-function (conditional Dicer deletion in macrophages), miRNA expression profiling, ETS2 knockdown/overexpression, angiogenesis and tumor growth assays, target gene validation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — pathway placement by loss-of-function, confirmed by miRNA overexpression and target gene analysis","pmids":["25241894"],"is_preprint":false},{"year":2016,"finding":"ETS2 directly binds regulatory sequences of Ccl3, Ccl4, Cxcl4, Cxcl5, and Cxcl10 in pancreatic fibroblasts to control chemokine production and immune cell recruitment; conditional ablation of ETS2 in pancreatic fibroblasts decreased acinar-to-ductal metaplasia and altered immune infiltration.","method":"ChIP assay for ETS2 occupancy at chemokine promoters, conditional Ets2 ablation in fibroblasts, mouse ADM model (Kras G12D), flow cytometry of immune cell populations","journal":"Neoplasia","confidence":"High","confidence_rationale":"Tier 2 — direct promoter binding confirmed by ChIP plus in vivo conditional KO with immune phenotype","pmids":["27659014"],"is_preprint":false},{"year":2017,"finding":"ETS2 transcription factor-binding sites are enriched in the regulatory elements of snoRNA genes upregulated in p53 mutant osteosarcomas; homozygous deletion of ETS2 in p53 mutant mice strongly downregulates snoRNAs and reverses the prometastatic phenotype without affecting tumor development.","method":"RNA-seq of mouse osteosarcomas, regulatory element analysis, conditional ETS2 deletion in p53 mutant mice, phenotypic and transcriptomic analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — genome-wide analysis combined with in vivo conditional KO and defined molecular readouts","pmids":["29021240"],"is_preprint":false},{"year":2017,"finding":"ETS2 interaction with the co-repressor ZMYND11 (BS69) attenuates ETS2's transcriptional activation compared to ETS1, causing ETS2 to act as a weaker activator or repressor at shared target genes; this interaction is mediated by the ETS2 N-terminus and ZMYND11 expression levels determine oncogenic vs. tumor-suppressive roles of ETS2.","method":"ETS1/ETS2 cistrome comparison (ChIP-seq), ETS1 deletion lines, transcriptional activity assays, co-repressor interaction mapping, patient tumor expression correlation","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide cistrome data combined with direct interaction mapping and functional transcriptional assays","pmids":["28119415"],"is_preprint":false},{"year":2021,"finding":"ETS2 is phosphorylated and activated by ERK1/2 in response to hypertrophic stimuli in cardiomyocytes; conditional cardiomyocyte-specific ETS2 knockout protects mice from pressure overload-induced cardiac hypertrophy; ETS2 forms a complex with NFAT to stimulate transcription of hypertrophic genes including Rcan1.4 and miR-223, linking Erk1/2 and calcineurin/NFAT signaling pathways.","method":"Cardiomyocyte-specific Ets2 conditional knockout mice, calcineurin transgenic mouse model with ETS2 silencing, ChIP for ETS2 and NFAT at target promoters, co-immunoprecipitation of ETS2-NFAT complex, miR-223 functional studies","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 — in vivo conditional KO, direct complex identification by co-IP and ChIP, and multiple genetic model validation","pmids":["33821668"],"is_preprint":false},{"year":2024,"finding":"ETS2 is the causal gene at the chr21q22 inflammatory disease risk locus; overexpressing ETS2 in resting macrophages reproduces the inflammatory state of chr21q22-associated diseases, including upregulation of TNF and IL-23; functional genomics in primary human macrophages identified ETS2 as a central regulator of human inflammatory macrophage gene expression.","method":"Functional genomics in primary human macrophages, ETS2 overexpression, gene expression profiling, cellular signature database screening, pharmacological validation in vitro and ex vivo","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — primary human cell gain-of-function with genome-wide gene expression and pharmacological validation, high-citation foundational study","pmids":["38839969"],"is_preprint":false},{"year":1995,"finding":"ETS2 transactivates the CDC2 promoter through Ets-binding sites in its 5' flanking region; constitutive ETS2 expression in fibroblasts increases CDC2 expression, histone H1 kinase activity, and cyclin A levels, demonstrating a direct role for ETS2 in regulating G2/M cell cycle entry.","method":"Promoter-reporter transactivation assays, site-directed mutagenesis of EBS in cdc2 promoter, stable ETS2 expression in BALB/c3T3 cells, kinase activity assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — promoter mutagenesis plus functional kinase activity assays in cells stably expressing ETS2","pmids":["7867724"],"is_preprint":false},{"year":1996,"finding":"Constitutive expression of ETS2 in M1D+ myeloblast leukemia cells is sufficient to drive macrophage differentiation; ETS2 directly activates the junB promoter through Ets-binding sites, and dominant-negative ETS2 reduces junB transcription.","method":"Stable ETS2 expression in M1D+ cells, differentiation marker analysis (lysozyme, TNF-α), transient reporter assays with junB promoter, dominant-negative ETS2 transfection","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function with promoter-level mechanism identified","pmids":["8943340"],"is_preprint":false},{"year":2003,"finding":"ETS2 transactivates the beta-APP gene promoter via specific Ets-binding sites and cooperates with AP1; ETS2 transgenic mouse brains and fibroblasts overexpressing ETS2 show elevated beta-APP, increased presenilin-1, and increased beta-amyloid production.","method":"Reporter transactivation assays, EBS mutagenesis, ETS2 transgenic mouse brain analysis, Western blot for APP/presenilin-1/beta-amyloid","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — promoter mechanism defined and confirmed in vivo in transgenic mouse model","pmids":["12890557"],"is_preprint":false},{"year":2019,"finding":"ETS2 suppresses inflammatory cytokine production (IL-6, TNF-α, IFN-β) in macrophages by inhibiting ERK1/2, JNK, p38, and p65 MAPK/NF-κB signaling pathways, and also directly binds to and represses the IL-6 promoter; Ets2-deficient mice show exacerbated inflammation and increased susceptibility to CLP-induced sepsis.","method":"ETS2 knockdown and knockout macrophages, Ets2 conditional KO mice, CLP sepsis model, ChIP for ETS2 at IL-6 promoter, cytokine measurements, signaling pathway phosphorylation analysis","journal":"Aging","confidence":"High","confidence_rationale":"Tier 2 — in vivo KO model with multiple molecular mechanisms and direct promoter binding by ChIP","pmids":["31785145"],"is_preprint":false}],"current_model":"ETS2 is a sequence-specific transcriptional activator and repressor that functions as a nuclear effector of Ras/ERK/MAPK signaling: ERK1/2 directly phosphorylates a conserved N-terminal threonine (T72) in the Pointed domain region, which enhances transactivation by recruiting CBP/p300 coactivators and, in a phosphorylation-dependent manner, enables interaction with BRG1/SWI-SNF for transcriptional repression; ETS2 regulates invasion-associated proteases (MMPs, uPA), inflammatory cytokines (TNF, IL-6, miR-155), survival genes (Bcl-xL), and developmental programs (trophoblast/cardiac/hematopoietic) through direct binding to GGAA-containing Ets-binding sites, and can switch between oncogenic and tumor-suppressive functions depending on cellular ZMYND11 levels and competition with ETS1."},"narrative":{"teleology":[{"year":1988,"claim":"Establishing that ETS2 is an unstable nuclear phosphoprotein whose abundance is post-translationally controlled answered how ETS2 levels can be acutely regulated without transcriptional changes.","evidence":"Pulse-chase metabolic labeling and PKC activator treatment in cultured cells","pmids":["3062367"],"confidence":"High","gaps":["Identity of the E3 ligase/degradation pathway unknown","Phosphorylation sites mediating stabilization uncharacterized"]},{"year":1990,"claim":"Demonstrating that ETS2 is a sequence-specific transcriptional activator binding GGAA-containing Ets-binding sites, with rapid induction in macrophages and a role in Xenopus meiotic maturation, established ETS2 as a signal-responsive transcription factor functioning in both immune and developmental contexts.","evidence":"Gel-shift assays and reporter transactivation (HTLV-1 LTR); antisense oligonucleotide injection in Xenopus oocytes; Northern blots in macrophages stimulated with CSF, LPS, and PKC activators","pmids":["2209540","2255913","2186967"],"confidence":"High","gaps":["Upstream kinase cascade not yet defined","Endogenous mammalian target genes unknown"]},{"year":1992,"claim":"Identification of a C-terminal autoinhibitory domain that reduces DNA-binding 20–50-fold, and demonstration that the ETS2 DNA-binding domain acts as a dominant-negative blocking Ras-responsive transcription and CSF-1-dependent colony formation, placed ETS2 downstream of Ras in mitogenic signaling and revealed an intrinsic regulatory mechanism.","evidence":"Deletion mutagenesis with gel-shift assays; dominant-negative ETS2 in NIH 3T3 colony formation with epistasis rescue by c-Myc","pmids":["1409581","1448070"],"confidence":"High","gaps":["Identity of the kinase phosphorylating ETS2 in response to Ras not yet determined","Structural basis of autoinhibition unclear"]},{"year":1996,"claim":"Mapping the Ras-responsive phosphorylation to threonine-72 and showing this residue is required for transcriptional superactivation identified the key post-translational switch coupling MAPK signaling to ETS2 output; concurrently, ETS2 was shown to drive macrophage differentiation and directly activate junB.","evidence":"Phosphoamino acid analysis, T72A mutagenesis, reporter assays in NIH 3T3/RAW264; stable ETS2 expression in M1D+ myeloblasts with differentiation markers","pmids":["8552081","8943340"],"confidence":"High","gaps":["Direct kinase performing T72 phosphorylation not yet demonstrated","Coactivator mechanism downstream of pT72 unknown"]},{"year":1998,"claim":"ERK1/2 were identified as the direct T72 kinases, and phosphorylation was linked to activation of invasion-associated protease genes (uPA, MMP-9) through composite Ets-AP-1 sites; ETS2 knockout revealed embryonic lethality from trophoblast failure with defective MMP expression, establishing essential developmental and protease-regulatory roles.","evidence":"In vitro kinase assays with recombinant ERK1/2 and ETS2, phospho-T72 antibody, MEK inhibitor PD98059; Ets2 gene-targeted knockout mice rescued by tetraploid aggregation; promoter mutagenesis of uPA/MMP-9 reporters","pmids":["9710599","9639404","9573048"],"confidence":"High","gaps":["How ETS2 recruits coactivators upon phosphorylation not resolved","Role of ETS2 in adult tissues beyond placenta unclear"]},{"year":1999,"claim":"Discovery that phosphorylated ETS2 physically recruits CBP/p300 coactivators through two independent binding regions established the coactivator-recruitment mechanism by which MAPK-phosphorylated ETS2 enhances transcription.","evidence":"Co-immunoprecipitation, GST-pulldown with purified proteins, domain-mapping deletions, stromelysin reporter assays","pmids":["10358095"],"confidence":"High","gaps":["Whether phosphorylation is strictly required for CBP/p300 interaction not fully demonstrated here"]},{"year":2001,"claim":"ETS2 was shown to synergize with PU.1 to activate Bcl-xL transcription and promote macrophage survival, and CDK10 was identified as a Pointed-domain-specific interactor that inhibits ETS2 transactivation, revealing both a pro-survival target gene and a negative regulatory partner.","evidence":"Reporter assays and domain deletions for ETS2-PU.1 synergy on Bcl-xL promoter; CSF-1 withdrawal survival assays; yeast two-hybrid and co-IP for CDK10-ETS2 interaction","pmids":["11278399","11313931"],"confidence":"High","gaps":["Physiological conditions under which CDK10 inhibits ETS2 unclear","Kinase activity of CDK10 toward ETS2 not tested"]},{"year":2003,"claim":"The Pointed domain was found to recruit the BRG1/SWI-SNF complex in a phosphorylation-dependent manner for transcriptional repression (e.g., BRCA1), and ETS2 overexpression was shown to induce p53-dependent apoptosis, revealing dual activator-repressor functionality and a link to the p53 pathway.","evidence":"Affinity purification of Pointed-domain interactors, co-IP/pulldown for BRG1, BRCA1 reporter repression; ETS2 transgenic mice crossed with p53-null mice for genetic rescue of thymic apoptosis","pmids":["12637547","12554679"],"confidence":"High","gaps":["How ETS2 switches between CBP/p300 activation and BRG1-mediated repression at specific loci unclear","Mechanism by which ETS2 induces p53 not established"]},{"year":2003,"claim":"Demonstration that ETS2 T72A knock-in mice develop normally but show restricted mammary tumor growth with decreased stromal MMP expression established that MAPK-mediated ETS2 phosphorylation is dispensable for development but critical for tumor microenvironment function.","evidence":"T72A knock-in mice in multiple mammary tumor models (PyMT, Neu); macrophage MMP-9/MMP-3 analysis from tumor stroma","pmids":["14612405"],"confidence":"High","gaps":["Whether T72A affects all ETS2-dependent inflammatory programs not tested","Cell-autonomous versus stromal contributions not fully separated"]},{"year":2004,"claim":"Unbiased affinity chromatography confirmed that phospho-T72 preferentially recruits CBP/p300 in HeLa nuclear extracts, and the T72A knock-in was shown to reduce inflammatory macrophage gene expression and extend lifespan in a chronic inflammation model, unifying the phosphorylation-coactivator mechanism with in vivo inflammatory outcomes.","evidence":"Phospho-ETS2 affinity chromatography of HeLa nuclear extracts; Ets2A72 × Hcph me-v double mutant mice with macrophage gene expression and survival analysis","pmids":["15572696","15240733"],"confidence":"High","gaps":["Genome-wide identification of phospho-ETS2-dependent target genes not performed","PTEN-mediated suppression of ETS2 phosphorylation not tested in vivo"]},{"year":2007,"claim":"Conditional ETS2 knockout in trophoblast stem cells revealed that ETS2 maintains TS cell self-renewal through direct regulation of CDX2, a master trophoblast transcription factor, extending its developmental role beyond placental tissue structure to stem cell identity.","evidence":"Conditional Ets2 knockout in TS cells, gene expression and chromatin analysis for CDX2 as direct target","pmids":["17977525"],"confidence":"Medium","gaps":["Full set of ETS2-regulated stem cell genes not defined","Mechanism of ETS2 regulation of CDX2 (enhancer architecture) not detailed"]},{"year":2012,"claim":"ETS2 was found to mediate gain-of-function mutant p53 binding to ETS-binding sites genome-wide, activating TDP2 to confer etoposide resistance; separately, co-expression of ETS2 with MESP1 was sufficient to reprogram fibroblasts into cardiac progenitors, revealing a new oncogenic partnership and a cardiogenic function.","evidence":"ChIP-seq for mutant p53, co-IP with ETS2, TDP2 knockdown sensitization; lentiviral ETS2+MESP1 expression with cardiac marker and functional readouts in human fibroblasts","pmids":["22508727","22826236"],"confidence":"High","gaps":["Whether ETS2-mutant p53 axis operates across all p53 mutation types unknown","In vivo cardiac reprogramming with ETS2+MESP1 not tested"]},{"year":2013,"claim":"ETS2 was shown to directly activate miR-155 transcription in LPS-stimulated macrophages and to interact with the MLL histone methyltransferase complex to activate MMP1/MMP3 through H3K4me3 deposition, linking ETS2 to both microRNA regulation and epigenetic gene activation at invasion-related loci.","evidence":"ChIP for ETS2 at miR-155 promoter with Ets2-deficient mice; co-IP of ETS2-MLL complex, ChIP for H3K4me3 at MMP promoters upon HGF treatment","pmids":["24362029","23934123"],"confidence":"High","gaps":["Global landscape of ETS2-MLL co-regulated genes undefined","Whether ETS2-MLL interaction is phosphorylation-dependent not tested"]},{"year":2017,"claim":"ZMYND11 was identified as a co-repressor that attenuates ETS2 transcriptional output relative to ETS1, with ZMYND11 expression levels determining whether ETS2 acts as oncogene or tumor suppressor; separately, ETS2 was found to drive snoRNA expression and metastatic phenotype in p53-mutant osteosarcomas.","evidence":"ChIP-seq cistrome comparison of ETS1/ETS2, ZMYND11 interaction mapping and transcriptional assays; RNA-seq of p53-mutant osteosarcomas with conditional ETS2 deletion","pmids":["28119415","29021240"],"confidence":"High","gaps":["Structural basis of ZMYND11-ETS2 selectivity over ETS1 unknown","Mechanism connecting snoRNAs to metastasis not established"]},{"year":2019,"claim":"ETS2 was shown to function as an anti-inflammatory regulator by directly repressing the IL-6 promoter and inhibiting MAPK/NF-κB signaling in macrophages, with Ets2-deficient mice showing exacerbated sepsis, demonstrating context-dependent activator versus repressor roles in inflammation.","evidence":"ChIP for ETS2 at IL-6 promoter, conditional ETS2 KO mice in CLP sepsis model, signaling pathway phosphorylation analysis","pmids":["31785145"],"confidence":"High","gaps":["How ETS2 switches from inflammatory gene activator to repressor at specific promoters not mechanistically resolved","Discrepancy with pro-inflammatory ETS2 functions at other loci needs reconciliation"]},{"year":2021,"claim":"In cardiomyocytes, ERK1/2-phosphorylated ETS2 was shown to form a complex with NFAT to co-activate hypertrophic genes including Rcan1.4 and miR-223, and cardiomyocyte-specific ETS2 knockout protected from pressure overload-induced hypertrophy, establishing ETS2 as an integrator of ERK and calcineurin/NFAT signaling in cardiac disease.","evidence":"Cardiomyocyte-specific Ets2 conditional KO mice with pressure overload, co-IP of ETS2-NFAT, ChIP at Rcan1.4 and miR-223 promoters","pmids":["33821668"],"confidence":"High","gaps":["Full cardiac ETS2 targetome not defined","Whether pT72 is specifically required in cardiac hypertrophy not tested with knock-in"]},{"year":2024,"claim":"ETS2 was identified as the causal gene at the chr21q22 inflammatory disease risk locus; overexpression in primary human macrophages recapitulated the inflammatory transcriptional signature, establishing ETS2 as a master regulator of human inflammatory macrophage identity.","evidence":"Functional genomics in primary human macrophages, ETS2 overexpression with genome-wide gene expression profiling, pharmacological validation","pmids":["38839969"],"confidence":"High","gaps":["Therapeutic targeting strategies for ETS2 in inflammatory bowel disease not yet clinically validated","Whether ZMYND11 modulates disease-associated ETS2 activity not tested"]},{"year":null,"claim":"The mechanism by which ETS2 switches between transcriptional activation (via CBP/p300) and repression (via BRG1/SWI-SNF or ZMYND11) at specific genomic loci, and how this switching is dysregulated in disease, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of the ETS2 Pointed domain in complex with its diverse co-regulators","Genome-wide maps of ETS2 activator vs. repressor modes not available","Pharmacological approaches to selectively modulate ETS2 activity lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,6,9,24,28]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,7,9,10,11,13,14,16,22,24,30,32,36]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,2]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,11,13,14,22,24,26,30,32]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[19,24,27,28,32,36]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,10,21,23]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[15,16,20]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[33]}],"complexes":["SWI/SNF (BRG1/BAF57/INI1)","MLL histone methyltransferase complex"],"partners":["CBP","EP300","BRG1","ZMYND11","NFAT","PU.1","CDK10","TP53"],"other_free_text":[]},"mechanistic_narrative":"ETS2 is a sequence-specific transcription factor that integrates Ras/ERK/MAPK signaling with chromatin remodeling to control inflammatory, developmental, and cell-cycle gene programs. ERK1/2 phosphorylates ETS2 at a conserved N-terminal threonine (T72) within the Pointed domain, which promotes recruitment of CBP/p300 coactivators for transactivation and, context-dependently, BRG1/SWI-SNF for transcriptional repression; an autoinhibitory C-terminal domain additionally modulates DNA-binding affinity [PMID:9710599, PMID:15572696, PMID:12637547, PMID:1409581]. ETS2 directly activates invasion-associated proteases (MMP-9, MMP-3, uPA), inflammatory mediators (TNF, IL-6, miR-155, chemokines), survival genes (Bcl-xL), and developmental regulators (CDX2 in trophoblast stem cells, hypertrophic genes with NFAT in cardiomyocytes), and its phosphorylation-site knock-in (T72A) mice develop normally but show impaired mammary tumor progression and attenuated macrophage inflammatory responses [PMID:9573048, PMID:14612405, PMID:24362029, PMID:33821668, PMID:27659014]. ETS2 is the causal gene at the chr21q22 inflammatory disease risk locus, where its overexpression in human macrophages is sufficient to reproduce the inflammatory transcriptional signature of associated diseases [PMID:38839969]."},"prefetch_data":{"uniprot":{"accession":"P15036","full_name":"Protein C-ets-2","aliases":[],"length_aa":469,"mass_kda":53.0,"function":"Transcription factor activating transcription. Binds specifically the DNA GGAA/T core motif (Ets-binding site or EBS) in gene promoters and stimulates transcription","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P15036/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ETS2","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ETS2","total_profiled":1310},"omim":[{"mim_id":"617180","title":"CHITAYAT SYNDROME; CHYTS","url":"https://www.omim.org/entry/617180"},{"mim_id":"611888","title":"ETS2 REPRESSOR FACTOR; ERF","url":"https://www.omim.org/entry/611888"},{"mim_id":"611723","title":"CHROMOSOME 21 OPEN READING FRAME 24; C21ORF24","url":"https://www.omim.org/entry/611723"},{"mim_id":"611585","title":"TESCALCIN; TESC","url":"https://www.omim.org/entry/611585"},{"mim_id":"605474","title":"TOLL-LIKE RECEPTOR 9; TLR9","url":"https://www.omim.org/entry/605474"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Plasma membrane","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ETS2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P15036","domains":[{"cath_id":"1.10.150.50","chopping":"81-173","consensus_level":"high","plddt":83.5733,"start":81,"end":173},{"cath_id":"1.10.10.10","chopping":"350-460","consensus_level":"high","plddt":94.0875,"start":350,"end":460}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P15036","model_url":"https://alphafold.ebi.ac.uk/files/AF-P15036-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P15036-F1-predicted_aligned_error_v6.png","plddt_mean":62.84},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ETS2","jax_strain_url":"https://www.jax.org/strain/search?query=ETS2"},"sequence":{"accession":"P15036","fasta_url":"https://rest.uniprot.org/uniprotkb/P15036.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P15036/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P15036"}},"corpus_meta":[{"pmid":"8552081","id":"PMC_8552081","title":"Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8552081","citation_count":329,"is_preprint":false},{"pmid":"2847145","id":"PMC_2847145","title":"Mammalian ets-1 and ets-2 genes encode highly conserved proteins.","date":"1988","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2847145","citation_count":303,"is_preprint":false},{"pmid":"9573048","id":"PMC_9573048","title":"Defective trophoblast function in mice with a targeted mutation of Ets2.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9573048","citation_count":255,"is_preprint":false},{"pmid":"20978205","id":"PMC_20978205","title":"EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20978205","citation_count":239,"is_preprint":false},{"pmid":"2209540","id":"PMC_2209540","title":"The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1.","date":"1990","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2209540","citation_count":236,"is_preprint":false},{"pmid":"17332326","id":"PMC_17332326","title":"Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17332326","citation_count":232,"is_preprint":false},{"pmid":"9639404","id":"PMC_9639404","title":"The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor.","date":"1998","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9639404","citation_count":194,"is_preprint":false},{"pmid":"8183549","id":"PMC_8183549","title":"Differential expression of ets-1 and ets-2 proto-oncogenes during murine embryogenesis.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8183549","citation_count":191,"is_preprint":false},{"pmid":"22508727","id":"PMC_22508727","title":"Mutant p53 cooperates with ETS2 to promote etoposide resistance.","date":"2012","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/22508727","citation_count":173,"is_preprint":false},{"pmid":"15572696","id":"PMC_15572696","title":"Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15572696","citation_count":169,"is_preprint":false},{"pmid":"8596630","id":"PMC_8596630","title":"Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8596630","citation_count":164,"is_preprint":false},{"pmid":"22826236","id":"PMC_22826236","title":"Transcription factors ETS2 and MESP1 transdifferentiate human dermal fibroblasts into cardiac progenitors.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22826236","citation_count":161,"is_preprint":false},{"pmid":"1448070","id":"PMC_1448070","title":"Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1448070","citation_count":153,"is_preprint":false},{"pmid":"19411629","id":"PMC_19411629","title":"Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19411629","citation_count":152,"is_preprint":false},{"pmid":"1409581","id":"PMC_1409581","title":"An inhibitory carboxyl-terminal domain in Ets-1 and Ets-2 mediates differential binding of ETS family factors to promoter sequences of the mb-1 gene.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1409581","citation_count":146,"is_preprint":false},{"pmid":"20671229","id":"PMC_20671229","title":"Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells.","date":"2010","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20671229","citation_count":130,"is_preprint":false},{"pmid":"23659968","id":"PMC_23659968","title":"ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23659968","citation_count":127,"is_preprint":false},{"pmid":"10358095","id":"PMC_10358095","title":"p300/cAMP-responsive element-binding protein interactions with ets-1 and ets-2 in the transcriptional activation of the human stromelysin promoter.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10358095","citation_count":123,"is_preprint":false},{"pmid":"38839969","id":"PMC_38839969","title":"A disease-associated gene desert directs macrophage inflammation through ETS2.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38839969","citation_count":106,"is_preprint":false},{"pmid":"19168790","id":"PMC_19168790","title":"ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19168790","citation_count":97,"is_preprint":false},{"pmid":"11313931","id":"PMC_11313931","title":"Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11313931","citation_count":93,"is_preprint":false},{"pmid":"24362029","id":"PMC_24362029","title":"The role of Ets2 transcription factor in the induction of microRNA-155 (miR-155) by lipopolysaccharide and its targeting by interleukin-10.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24362029","citation_count":91,"is_preprint":false},{"pmid":"10212281","id":"PMC_10212281","title":"Regulation of the human interleukin-5 promoter by Ets transcription factors. Ets1 and Ets2, but not Elf-1, cooperate with GATA3 and HTLV-I Tax1.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10212281","citation_count":89,"is_preprint":false},{"pmid":"9710599","id":"PMC_9710599","title":"Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulating factor 1/c-fms signaling.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9710599","citation_count":88,"is_preprint":false},{"pmid":"8510925","id":"PMC_8510925","title":"Transactivation of GATA-1 promoter with ETS1, ETS2 and ERGB/Hu-FLI-1 proteins: stabilization of the ETS1 protein binding on GATA-1 promoter sequences by monoclonal antibody.","date":"1993","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8510925","citation_count":87,"is_preprint":false},{"pmid":"21989915","id":"PMC_21989915","title":"Analysis of gene networks in white adipose tissue development reveals a role for ETS2 in adipogenesis.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21989915","citation_count":85,"is_preprint":false},{"pmid":"3062367","id":"PMC_3062367","title":"A short-lived nuclear phosphoprotein encoded by the human ets-2 proto-oncogene is stabilized by activation of protein kinase C.","date":"1988","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3062367","citation_count":84,"is_preprint":false},{"pmid":"12554679","id":"PMC_12554679","title":"ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway.","date":"2003","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12554679","citation_count":80,"is_preprint":false},{"pmid":"15745955","id":"PMC_15745955","title":"ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons.","date":"2005","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15745955","citation_count":77,"is_preprint":false},{"pmid":"12637368","id":"PMC_12637368","title":"Ets-1 and Ets-2 transcription factors are essential for normal coronary and myocardial development in chicken embryos.","date":"2003","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/12637368","citation_count":76,"is_preprint":false},{"pmid":"2405393","id":"PMC_2405393","title":"Molecular and functional characterization of the promoter of ETS2, the human c-ets-2 gene.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2405393","citation_count":74,"is_preprint":false},{"pmid":"24069250","id":"PMC_24069250","title":"Ets-2 regulates cell apoptosis via the Akt pathway, through the regulation of urothelial cancer associated 1, a long non-coding RNA, in bladder cancer cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24069250","citation_count":70,"is_preprint":false},{"pmid":"12637547","id":"PMC_12637547","title":"Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12637547","citation_count":70,"is_preprint":false},{"pmid":"33821668","id":"PMC_33821668","title":"Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.","date":"2021","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/33821668","citation_count":67,"is_preprint":false},{"pmid":"17977525","id":"PMC_17977525","title":"Ets2 is required for trophoblast stem cell self-renewal.","date":"2007","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17977525","citation_count":65,"is_preprint":false},{"pmid":"12095911","id":"PMC_12095911","title":"PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12095911","citation_count":63,"is_preprint":false},{"pmid":"2882955","id":"PMC_2882955","title":"Genetic mapping of Prm-1, Igl-1, Smst, Mtv-6, Sod-1, and Ets-2 and localization of the Down syndrome region on mouse chromosome 16.","date":"1987","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2882955","citation_count":61,"is_preprint":false},{"pmid":"25241894","id":"PMC_25241894","title":"CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25241894","citation_count":61,"is_preprint":false},{"pmid":"2834248","id":"PMC_2834248","title":"The Drosophila ets-2 gene: molecular structure, chromosomal localization, and developmental expression.","date":"1988","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/2834248","citation_count":57,"is_preprint":false},{"pmid":"2186967","id":"PMC_2186967","title":"Rapid and transient expression of Ets2 in mature macrophages following stimulation with cMGF, LPS, and PKC activators.","date":"1990","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/2186967","citation_count":57,"is_preprint":false},{"pmid":"16142752","id":"PMC_16142752","title":"Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.","date":"2005","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/16142752","citation_count":57,"is_preprint":false},{"pmid":"9500466","id":"PMC_9500466","title":"Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9500466","citation_count":56,"is_preprint":false},{"pmid":"29021240","id":"PMC_29021240","title":"Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.","date":"2017","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/29021240","citation_count":56,"is_preprint":false},{"pmid":"18059336","id":"PMC_18059336","title":"Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18059336","citation_count":55,"is_preprint":false},{"pmid":"12560478","id":"PMC_12560478","title":"Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide.","date":"2003","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/12560478","citation_count":54,"is_preprint":false},{"pmid":"23934123","id":"PMC_23934123","title":"HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23934123","citation_count":53,"is_preprint":false},{"pmid":"28624205","id":"PMC_28624205","title":"ATG7 Overexpression Is Crucial for Tumorigenic Growth of Bladder Cancer In Vitro and In Vivo by Targeting the ETS2/miRNA196b/FOXO1/p27 Axis.","date":"2017","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/28624205","citation_count":53,"is_preprint":false},{"pmid":"9122038","id":"PMC_9122038","title":"Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer.","date":"1997","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/9122038","citation_count":52,"is_preprint":false},{"pmid":"14612405","id":"PMC_14612405","title":"Ets2-dependent stromal regulation of mouse mammary tumors.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14612405","citation_count":52,"is_preprint":false},{"pmid":"22298639","id":"PMC_22298639","title":"Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells.","date":"2012","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22298639","citation_count":50,"is_preprint":false},{"pmid":"11280797","id":"PMC_11280797","title":"Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11280797","citation_count":50,"is_preprint":false},{"pmid":"2137553","id":"PMC_2137553","title":"Phosphorylation of the ETS-2 protein: regulation by the T-cell antigen receptor-CD3 complex.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2137553","citation_count":48,"is_preprint":false},{"pmid":"10485465","id":"PMC_10485465","title":"A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10485465","citation_count":48,"is_preprint":false},{"pmid":"9668063","id":"PMC_9668063","title":"Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9668063","citation_count":48,"is_preprint":false},{"pmid":"11278399","id":"PMC_11278399","title":"Bcl-XL expression correlates with primary macrophage differentiation, activation of functional competence, and survival and results from synergistic transcriptional activation by Ets2 and PU.1.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278399","citation_count":48,"is_preprint":false},{"pmid":"14678752","id":"PMC_14678752","title":"Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis.","date":"2003","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/14678752","citation_count":47,"is_preprint":false},{"pmid":"15240733","id":"PMC_15240733","title":"Activated Ets2 is required for persistent inflammatory responses in the motheaten viable model.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15240733","citation_count":46,"is_preprint":false},{"pmid":"29974077","id":"PMC_29974077","title":"Aberrant expression of ETS1 and ETS2 proteins in cancer.","date":"2018","source":"Cancer reports and reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29974077","citation_count":44,"is_preprint":false},{"pmid":"18848526","id":"PMC_18848526","title":"Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18848526","citation_count":44,"is_preprint":false},{"pmid":"2255913","id":"PMC_2255913","title":"Requirement of ets-2 expression for Xenopus oocyte maturation.","date":"1990","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2255913","citation_count":43,"is_preprint":false},{"pmid":"7523384","id":"PMC_7523384","title":"Ets-2 and c-Myb act independently in regulating expression of the hematopoietic stem cell antigen CD34.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7523384","citation_count":40,"is_preprint":false},{"pmid":"11573964","id":"PMC_11573964","title":"Ets-2 is induced by oxidative stress and sensitizes cells to H(2)O(2)-induced apoptosis: implications for Down's syndrome.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11573964","citation_count":40,"is_preprint":false},{"pmid":"18094719","id":"PMC_18094719","title":"The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18094719","citation_count":38,"is_preprint":false},{"pmid":"8943340","id":"PMC_8943340","title":"Constitutive c-ets2 expression in M1D+ myeloblast leukemic cells induces their differentiation to macrophages.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8943340","citation_count":37,"is_preprint":false},{"pmid":"12391198","id":"PMC_12391198","title":"The role of the Ets2 transcription factor in the proliferation, maturation, and survival of mouse thymocytes.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12391198","citation_count":36,"is_preprint":false},{"pmid":"19179380","id":"PMC_19179380","title":"Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis.","date":"2009","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/19179380","citation_count":36,"is_preprint":false},{"pmid":"31785145","id":"PMC_31785145","title":"Ets2 suppresses inflammatory cytokines through MAPK/NF-κB signaling and directly binds to the IL-6 promoter in macrophages.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31785145","citation_count":34,"is_preprint":false},{"pmid":"17921261","id":"PMC_17921261","title":"Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer.","date":"2007","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17921261","citation_count":34,"is_preprint":false},{"pmid":"32677671","id":"PMC_32677671","title":"RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer.","date":"2020","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/32677671","citation_count":33,"is_preprint":false},{"pmid":"27659014","id":"PMC_27659014","title":"Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia.","date":"2016","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/27659014","citation_count":32,"is_preprint":false},{"pmid":"19407855","id":"PMC_19407855","title":"Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.","date":"2009","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/19407855","citation_count":32,"is_preprint":false},{"pmid":"31872468","id":"PMC_31872468","title":"Exosomal miR-663b targets Ets2-repressor factor to promote proliferation and the epithelial-mesenchymal transition of bladder cancer cells.","date":"2020","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/31872468","citation_count":32,"is_preprint":false},{"pmid":"7867724","id":"PMC_7867724","title":"ets-2 regulates cdc2 kinase activity in mammalian cells: coordinated expression of cdc2 and cyclin A.","date":"1995","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/7867724","citation_count":31,"is_preprint":false},{"pmid":"12168840","id":"PMC_12168840","title":"Expression of ets-1 and ets-2 in colonic neoplasms.","date":"2002","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12168840","citation_count":30,"is_preprint":false},{"pmid":"12890557","id":"PMC_12890557","title":"The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12890557","citation_count":30,"is_preprint":false},{"pmid":"23789107","id":"PMC_23789107","title":"The Rho-GEF Trio regulates a novel pro-inflammatory pathway through the transcription factor Ets2.","date":"2013","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/23789107","citation_count":30,"is_preprint":false},{"pmid":"26274316","id":"PMC_26274316","title":"VEGFA Expression Is Inhibited by Arsenic Trioxide in HUVECs through the Upregulation of Ets-2 and miRNA-126.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26274316","citation_count":29,"is_preprint":false},{"pmid":"2216458","id":"PMC_2216458","title":"The human ETS-2 gene promoter: molecular dissection and nuclease hypersensitivity.","date":"1990","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/2216458","citation_count":29,"is_preprint":false},{"pmid":"21425406","id":"PMC_21425406","title":"Ets2 regulates colonic stem cells and sensitivity to tumorigenesis.","date":"2011","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/21425406","citation_count":28,"is_preprint":false},{"pmid":"24277931","id":"PMC_24277931","title":"Transcription factor Ets1, but not the closely related factor Ets2, inhibits antibody-secreting cell differentiation.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24277931","citation_count":28,"is_preprint":false},{"pmid":"16799155","id":"PMC_16799155","title":"The transcriptional ETS2 repressor factor associates with active and inactive Erks through distinct FXF motifs.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16799155","citation_count":28,"is_preprint":false},{"pmid":"12511603","id":"PMC_12511603","title":"A central role for Ets-2 in the transcriptional regulation and cyclic adenosine 5'-monophosphate responsiveness of the human chorionic gonadotropin-beta subunit gene.","date":"2003","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12511603","citation_count":28,"is_preprint":false},{"pmid":"9918849","id":"PMC_9918849","title":"Evidence against the current hypothesis of \"gene dosage effects\" of trisomy 21: ets-2, encoded on chromosome 21\" is not overexpressed in hearts of patients with Down Syndrome.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9918849","citation_count":28,"is_preprint":false},{"pmid":"31071529","id":"PMC_31071529","title":"MicroRNA-146b Overexpression Promotes Human Bladder Cancer Invasion via Enhancing ETS2-Mediated mmp2 mRNA Transcription.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31071529","citation_count":27,"is_preprint":false},{"pmid":"31841990","id":"PMC_31841990","title":"Kcnq1ot1/miR-381-3p/ETS2 Axis Regulates Inflammation in Mouse Models of Acute Respiratory Distress Syndrome.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31841990","citation_count":27,"is_preprint":false},{"pmid":"19566835","id":"PMC_19566835","title":"Ets2 transcription factor, telomerase activity and breast cancer.","date":"2009","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19566835","citation_count":26,"is_preprint":false},{"pmid":"28119415","id":"PMC_28119415","title":"Interaction with ZMYND11 mediates opposing roles of Ras-responsive transcription factors ETS1 and ETS2.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28119415","citation_count":25,"is_preprint":false},{"pmid":"21763315","id":"PMC_21763315","title":"RuvBl2 cooperates with Ets2 to transcriptionally regulate hTERT in colon cancer.","date":"2011","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/21763315","citation_count":25,"is_preprint":false},{"pmid":"16380248","id":"PMC_16380248","title":"Ets2 transcription factor in normal and neoplastic human breast tissue.","date":"2005","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/16380248","citation_count":25,"is_preprint":false},{"pmid":"26925389","id":"PMC_26925389","title":"Mutant p53 and ETS2, a Tale of Reciprocity.","date":"2016","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26925389","citation_count":24,"is_preprint":false},{"pmid":"19764029","id":"PMC_19764029","title":"Complex contributions of Ets2 to craniofacial and thymus phenotypes of trisomic \"Down syndrome\" mice.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19764029","citation_count":24,"is_preprint":false},{"pmid":"19939245","id":"PMC_19939245","title":"Ets-2 and p53 mediate cAMP-induced MMP-2 expression, activity and trophoblast invasion.","date":"2009","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/19939245","citation_count":23,"is_preprint":false},{"pmid":"9822660","id":"PMC_9822660","title":"Selective inhibition of prolactin gene transcription by the ETS-2 repressor factor.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9822660","citation_count":23,"is_preprint":false},{"pmid":"15217985","id":"PMC_15217985","title":"Regulation of interferon-tau (IFN-tau) gene promoters by growth factors that target the Ets-2 composite enhancer: a possible model for maternal control of IFN-tau production by the conceptus during early pregnancy.","date":"2004","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15217985","citation_count":23,"is_preprint":false},{"pmid":"20569982","id":"PMC_20569982","title":"New insights for Ets2 function in trophoblast using lentivirus-mediated gene knockdown in trophoblast stem cells.","date":"2010","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/20569982","citation_count":22,"is_preprint":false},{"pmid":"25446535","id":"PMC_25446535","title":"Elf5 and Ets2 maintain the mouse extraembryonic ectoderm in a dosage dependent synergistic manner.","date":"2014","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25446535","citation_count":21,"is_preprint":false},{"pmid":"37171262","id":"PMC_37171262","title":"ETS2 promotes cardiomyocyte apoptosis and autophagy in heart failure by regulating lncRNA TUG1/miR-129-5p/ATG7 axis.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37171262","citation_count":21,"is_preprint":false},{"pmid":"24968297","id":"PMC_24968297","title":"MicroRNA 17-92 cluster mediates ETS1 and ETS2-dependent RAS-oncogenic transformation.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24968297","citation_count":20,"is_preprint":false},{"pmid":"10666682","id":"PMC_10666682","title":"Expression of the transcription factor ETS2 in brain of patients with Down syndrome--evidence against the overexpression-gene dosage hypothesis.","date":"1999","source":"Journal of neural transmission. Supplementum","url":"https://pubmed.ncbi.nlm.nih.gov/10666682","citation_count":20,"is_preprint":false},{"pmid":"27195074","id":"PMC_27195074","title":"The C-ETS2-TFEB Axis Promotes Neuron Survival under Oxidative Stress by Regulating Lysosome Activity.","date":"2016","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/27195074","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47603,"output_tokens":8739,"usd":0.136947},"stage2":{"model":"claude-opus-4-6","input_tokens":12572,"output_tokens":4754,"usd":0.272565},"total_usd":0.409512,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Ras signaling induces phosphorylation of a conserved threonine residue (T72 in ETS2, T38 in ETS1) that is required for Ras-mediated transcriptional superactivation of Ets-responsive reporters containing Ets-AP-1 binding sites.\",\n      \"method\": \"Phosphoamino acid analysis of radiolabeled ETS2, site-directed mutagenesis (T72A), transient transfection reporter assays in NIH 3T3 and RAW264 cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro phosphorylation confirmed by phosphoamino acid analysis plus mutagenesis abolishing activity, replicated across multiple labs\",\n      \"pmids\": [\"8552081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"ETS2 protein is a short-lived (half-life ~20 min) nuclear phosphoprotein; activation of protein kinase C (PKC) by TPA or diacylglycerol stabilizes ETS2 protein (half-life >2 h) through a post-translational mechanism without significantly increasing mRNA levels.\",\n      \"method\": \"Pulse-chase metabolic labeling, cycloheximide chase, PKC inhibitor H7 treatment, subcellular fractionation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical methods in a single study demonstrating PKC-dependent protein stabilization\",\n      \"pmids\": [\"3062367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"ETS2 (and ETS1) function as sequence-specific transcriptional activators by binding to GGAA-containing Ets-binding sites in the HTLV-1 LTR enhancer region; nuclear localization is required for transactivation activity.\",\n      \"method\": \"Transient co-transfection CAT reporter assays, gel-shift DNA-binding assay, competition experiments with oligonucleotides, nuclear localization mutant analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — DNA-binding and transactivation confirmed by multiple orthogonal methods\",\n      \"pmids\": [\"2209540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"ETS2 expression is required for hormone-induced meiotic maturation (germinal vesicle breakdown) in Xenopus oocytes, as antisense oligonucleotide-mediated degradation of ets-2 mRNA blocks this process.\",\n      \"method\": \"Antisense oligonucleotide injection into Xenopus oocytes, hormone-induced maturation assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean loss-of-function with defined cellular phenotype; Xenopus ortholog consistent with mammalian ETS2\",\n      \"pmids\": [\"2255913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"ETS2 expression is rapidly and transiently induced in macrophages in response to CSF (cMGF), LPS, and PKC activators; PKC down-regulation blunts cMGF-induced ETS2 expression, implicating PKC in the signaling pathway.\",\n      \"method\": \"Northern blot, protein analysis, PKC inhibition/down-regulation experiments in chicken bone marrow macrophages, human monocytes, and mouse peritoneal macrophages\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell types and pharmacological inhibition with consistent results\",\n      \"pmids\": [\"2186967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"ETS2 phosphorylation is induced within 5 min by T-cell antigen receptor-CD3 complex activation in Jurkat cells, mediated through calcium (mimicked by Ca2+ ionophores), detected as a mobility shift from 54 to 56 kDa.\",\n      \"method\": \"32P metabolic labeling, SDS-PAGE mobility shift, antibody stimulation of TCR-CD3, Ca2+ ionophore treatment\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical detection with pharmacological dissection of pathway\",\n      \"pmids\": [\"2137553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The carboxyl-terminal domain of ETS2 (and ETS1) acts as an inhibitory domain that reduces DNA binding affinity; deletion of as few as 16 C-terminal amino acids increases DNA binding 20–50-fold, and this domain acts directly on DNA binding rather than through homodimerization.\",\n      \"method\": \"Gel-shift binding assay, deletion mutagenesis, in vitro cotranslation experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis defining the inhibitory domain\",\n      \"pmids\": [\"1409581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The ETS2 DNA-binding domain acts as a dominant-negative to suppress Ras-responsive enhancer activity and inhibit CSF-1-dependent colony formation; ectopic ETS2 rescues the c-myc response that is impaired when Ets-LacZ is expressed, placing ETS2 upstream of c-Myc in the CSF-1/Ras mitogenic signaling cascade.\",\n      \"method\": \"Stable expression of Ets-LacZ fusion in NIH 3T3 cells, colony formation assays, Northern blot analysis of c-ets-2, c-jun, c-fos, c-myc; rescue by c-myc overexpression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by dominant-negative and rescue experiments with defined phenotypic readouts\",\n      \"pmids\": [\"1448070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"MAP kinases p42/p44 (ERK1/2) directly phosphorylate ETS2 at T72 in response to CSF-1/c-fms signaling, leading to persistent ETS2 phosphorylation and activation of the uPA gene target; the RAF/MAP kinase pathway is specifically required for both ETS2 expression and post-translational activation.\",\n      \"method\": \"Phospho-specific antibody (anti-pT72), in vitro kinase assay with recombinant ETS2, MEK inhibitor PD98059, immune depletion of MAP kinases, conditional Raf expression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay combined with phospho-specific antibody detection and pharmacological inhibition\",\n      \"pmids\": [\"9710599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ETS2 (and ETS1) transactivate the uPA and MMP-9 promoters in response to EGF through composite Ets-AP-1 binding sites; mutation of the conserved threonine (T75 of chicken ETS2, equivalent to T72) abolishes this EGF-dependent cooperation, linking EGF→Ras/ERK→ETS2 to invasion-associated protease expression.\",\n      \"method\": \"Reporter transfection assays, site-directed mutagenesis of Ets and AP-1 binding sites and T75 phosphorylation site, ETS2 expression vectors\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — promoter mutagenesis and phosphorylation site mutation with functional readouts\",\n      \"pmids\": [\"9639404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Targeted deletion of the ETS2 DNA-binding domain causes embryonic lethality due to defective trophoblast/extraembryonic tissue function, with failure of ectoplacental cone proliferation and deficient MMP-9 expression; rescued Ets2-deficient fibroblasts fail to induce MMP-13 and MMP-3 in response to FGF, and ectopic ETS2 restores this MMP expression.\",\n      \"method\": \"Gene targeting/knockout mice, tetraploid aggregation rescue, Northern blot for MMPs, ectopic ETS2 re-expression in knockout fibroblasts\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined phenotype, rescue by re-expression, replicated across multiple cell types and conditions\",\n      \"pmids\": [\"9573048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ETS2 physically interacts with the coactivators p300 and CBP in vivo; two independent regions of p300/CBP (aa 328–596 and aa 1678–2370) directly bind the ETS2 transactivation domain in vitro and in vivo, enabling coactivator recruitment to the stromelysin promoter.\",\n      \"method\": \"Co-immunoprecipitation from cells, GST-pulldown with purified proteins, reporter transactivation assays, domain-mapping deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct in vitro binding with purified proteins confirmed by reciprocal co-IP and functional reporter assays\",\n      \"pmids\": [\"10358095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CDK10, a CDC2-related kinase, physically interacts with the N-terminus (Pointed domain) of ETS2 and inhibits ETS2 transactivation activity; the interaction is ETS2-specific (CDK10 does not bind ETS1 in yeast two-hybrid) and requires an intact Pointed domain.\",\n      \"method\": \"Yeast two-hybrid, in vitro binding (GST-pulldown), co-immunoprecipitation from mammalian cells, transactivation reporter assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — yeast two-hybrid plus in vitro and in vivo binding with functional consequence\",\n      \"pmids\": [\"11313931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ETS2 interacts with components of the mammalian SWI/SNF chromatin remodeling complex (BRG-1, BAF57/p50, INI1) through its Pointed domain to form a repressor complex; BRG-1 directly binds the ETS2 Pointed domain in a phosphorylation-dependent manner, and the ETS2/BRG-1 complex represses the BRCA1 promoter.\",\n      \"method\": \"Biochemical affinity purification of Pointed-domain-interacting proteins, co-immunoprecipitation, in vitro pulldown, reporter repression assays, conditional ETS2 overexpression in MCF-7\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — unbiased biochemical screen followed by direct binding, co-IP, and functional gene repression assays\",\n      \"pmids\": [\"12637547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ERK1/2-mediated phosphorylation of ETS2 (and ETS1) at the conserved N-terminal threonine (T72) enhances transactivation by promoting preferential recruitment of the coactivators CBP and p300; this interaction requires both the phosphoacceptor site and the Pointed domain, and was identified by unbiased affinity chromatography of HeLa nuclear extracts.\",\n      \"method\": \"Affinity chromatography of HeLa nuclear extracts using phospho- vs. mock-ETS2 as ligand, direct binding with purified proteins, co-immunoprecipitation from cells, MEK1-stimulated reporter assays, CBP co-expression experiments\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — unbiased biochemical screen with reconstituted direct binding and in vivo functional validation\",\n      \"pmids\": [\"15572696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ETS2 overexpression induces apoptosis through the p53 pathway; genetic rescue by p53 knockout (crossing ETS2 transgenic mice with p53-/- mice) abolishes the thymic apoptosis phenotype, placing ETS2 upstream of p53-dependent apoptosis.\",\n      \"method\": \"ETS2 transgenic mice, p53-/- crossing/genetic rescue, p53 and downstream factor expression analysis, HeLa transfection with p53 and ETS2\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with functional rescue and orthologous cell line data\",\n      \"pmids\": [\"12554679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ETS2 and PU.1 synergistically transactivate the Bcl-xL promoter in macrophages; this synergy depends on the transactivation domains of both proteins and is specific (ETS1 does not substitute for ETS2), and overexpression of both factors increases macrophage survival upon CSF-1 withdrawal.\",\n      \"method\": \"Reporter transactivation assays, domain deletion analysis, retroviral overexpression in bone marrow-derived macrophages, CSF-1 withdrawal survival assays, Bax-induced apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including functional cellular rescue and promoter mechanistic analysis\",\n      \"pmids\": [\"11278399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PTEN suppresses insulin-stimulated ETS2 phosphorylation (at the T72 MAP kinase site) through inhibition of ERK/MAP kinase signaling independently of PI3K/Akt, and this functional suppression is dependent on PTEN phosphatase activity; phosphatase-dead PTEN fails to block ETS2 phosphorylation or uPA RRE activation.\",\n      \"method\": \"Phospho-specific ETS2 antibody (anti-pT72), MEK inhibitor vs PI3K inhibitor treatment, PTEN overexpression, uPA RRE reporter assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of pathways with phospho-specific readout and functional reporter confirmation\",\n      \"pmids\": [\"12095911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MAP kinase phosphorylation of ETS2 at T72 is required for mammary tumor progression; knock-in mice with T72A mutation (Ets2A72) develop normally but show restricted mammary tumor growth, with decreased stromal MMP-9 and MMP-3 expression in macrophages, identifying ETS2 pT72 as acting in tumor stroma.\",\n      \"method\": \"Gene-targeted knock-in mice (T72A point mutation), mammary tumor models (polyoma middle T, Neu, Neu+VEGF), tumor transplantation into fat pads, macrophage MMP expression analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — precise phosphorylation site knock-in with multiple tumor models and defined molecular readouts\",\n      \"pmids\": [\"14612405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Constitutive phosphorylation of ETS2 at T72 is required for persistent inflammatory macrophage responses in the motheaten viable model; Ets2A72 allele (T72A knock-in) reduces inflammatory gene expression (TNF-α, CCL3, MMP-9, integrin αM, Bcl-X), increases macrophage apoptosis, and extends lifespan of me-v mice.\",\n      \"method\": \"Genetic double-mutant mice (Ets2A72 × Hcph me-v), alveolar macrophage gene expression analysis, LPS stimulation of bone marrow-derived macrophages, macrophage apoptosis assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic epistasis with multiple molecular readouts and defined phosphorylation site\",\n      \"pmids\": [\"15240733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ETS2 directly activates Bcl-xL transcription in osteoclasts; TNF stimulates ETS2 expression in osteoclasts, which in turn upregulates Bcl-xL, protecting osteoclasts from bisphosphonate-induced apoptosis; dominant-negative ETS2 blocks this TNF-protective effect.\",\n      \"method\": \"Retrovirus-mediated ETS2 overexpression in osteoclasts, dominant-negative ETS2 construct, in vitro osteoclast survival assay, Bcl-xL mRNA measurement, TNF-Tg mouse model\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with defined molecular target in primary osteoclasts\",\n      \"pmids\": [\"16142752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ETS2 is required for trophoblast stem (TS) cell self-renewal; conditional inactivation of ETS2 reduces TS cell growth and promotes differentiation; a direct target in TS cells is CDX2, a master regulator of TS cell state, identified by chromatin analysis.\",\n      \"method\": \"Conditional Ets2 knockout via targeted allele, gene expression analysis, identification of CDX2 as direct ETS2 target\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined cellular phenotype and direct target identification\",\n      \"pmids\": [\"17977525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Mutant p53 (gain-of-function) interacts with ETS2 to regulate gene expression through ETS-binding sites in promoters; ETS2 mediates mutant p53 binding to EBS motifs and together they activate TDP2 transcription, contributing to etoposide resistance.\",\n      \"method\": \"ChIP-seq (genome-wide mutant p53 binding), reporter assays with EBS motifs, co-immunoprecipitation, TDP2 knockdown sensitization assays, gene expression analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide binding analysis, direct interaction, and functional drug sensitivity assays\",\n      \"pmids\": [\"22508727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Co-expression of ETS2 and MESP1 transcription factors reprograms human dermal fibroblasts into cardiac progenitors expressing KDR+ cardiac mesoderm marker, core cardiac transcription factors, Ca2+ transients, and sarcomeres; neither factor alone is sufficient.\",\n      \"method\": \"Lentivirus-mediated forced expression, marker expression analysis (KDR, cardiac TFs), Ca2+ imaging, sarcomere detection, embryonic stem cell cardiopoiesis assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional readouts with defined transcription factor combination\",\n      \"pmids\": [\"22826236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ETS2 directly binds to the promoters of miR-155 in macrophages in response to LPS; ETS2-deficient mice show decreased miR-155 induction by LPS; IL-10 inhibits ETS2 induction, reducing its activity on the miR-155 promoter.\",\n      \"method\": \"Promoter truncation/mutational analysis, ChIP assay, ETS2-deficient mice, LPS stimulation, IL-10 treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding by ChIP confirmed by in vivo mouse model and promoter mutagenesis\",\n      \"pmids\": [\"24362029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ETS2 suppresses MET phosphorylation and MET-dependent cell invasion in lung cancer cells; ETS2 knockdown augments HGF-induced MET phosphorylation and invasion, placing ETS2 as a negative regulator of the HGF/MET pathway.\",\n      \"method\": \"RNAi knockdown, MET phosphorylation Western blot, invasion assays, MET knockdown epistasis experiment, microarray pathway analysis\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined molecular and cellular readouts and epistasis experiment\",\n      \"pmids\": [\"23659968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HGF-MET signaling leads to accumulation of ETS2, which interacts with the MLL histone methyltransferase complex to transactivate MMP1 and MMP3 promoters; ChIP assays show increased occupancy of the MLL-ETS2 complex and increased H3K4 trimethylation at these promoters upon HGF-MET activation.\",\n      \"method\": \"Co-immunoprecipitation of MLL-ETS2 complex, ChIP assay for complex occupancy and H3K4me3, HGF treatment of hepatocellular carcinoma cell lines, MLL knockout mouse phenotypic analysis\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct complex identification, ChIP for epigenetic mark, and in vivo genetic model\",\n      \"pmids\": [\"23934123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ETS2 in macrophages regulates the expression of miR-21, miR-29a, miR-142-3p, and miR-223 downstream of CSF1 signaling; CSF1-ETS2-induced microRNAs promote M2 reprogramming, angiogenesis, and metastatic tumor growth by targeting anti-angiogenic genes.\",\n      \"method\": \"Loss-of-function (conditional Dicer deletion in macrophages), miRNA expression profiling, ETS2 knockdown/overexpression, angiogenesis and tumor growth assays, target gene validation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway placement by loss-of-function, confirmed by miRNA overexpression and target gene analysis\",\n      \"pmids\": [\"25241894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ETS2 directly binds regulatory sequences of Ccl3, Ccl4, Cxcl4, Cxcl5, and Cxcl10 in pancreatic fibroblasts to control chemokine production and immune cell recruitment; conditional ablation of ETS2 in pancreatic fibroblasts decreased acinar-to-ductal metaplasia and altered immune infiltration.\",\n      \"method\": \"ChIP assay for ETS2 occupancy at chemokine promoters, conditional Ets2 ablation in fibroblasts, mouse ADM model (Kras G12D), flow cytometry of immune cell populations\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding confirmed by ChIP plus in vivo conditional KO with immune phenotype\",\n      \"pmids\": [\"27659014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ETS2 transcription factor-binding sites are enriched in the regulatory elements of snoRNA genes upregulated in p53 mutant osteosarcomas; homozygous deletion of ETS2 in p53 mutant mice strongly downregulates snoRNAs and reverses the prometastatic phenotype without affecting tumor development.\",\n      \"method\": \"RNA-seq of mouse osteosarcomas, regulatory element analysis, conditional ETS2 deletion in p53 mutant mice, phenotypic and transcriptomic analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide analysis combined with in vivo conditional KO and defined molecular readouts\",\n      \"pmids\": [\"29021240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ETS2 interaction with the co-repressor ZMYND11 (BS69) attenuates ETS2's transcriptional activation compared to ETS1, causing ETS2 to act as a weaker activator or repressor at shared target genes; this interaction is mediated by the ETS2 N-terminus and ZMYND11 expression levels determine oncogenic vs. tumor-suppressive roles of ETS2.\",\n      \"method\": \"ETS1/ETS2 cistrome comparison (ChIP-seq), ETS1 deletion lines, transcriptional activity assays, co-repressor interaction mapping, patient tumor expression correlation\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide cistrome data combined with direct interaction mapping and functional transcriptional assays\",\n      \"pmids\": [\"28119415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ETS2 is phosphorylated and activated by ERK1/2 in response to hypertrophic stimuli in cardiomyocytes; conditional cardiomyocyte-specific ETS2 knockout protects mice from pressure overload-induced cardiac hypertrophy; ETS2 forms a complex with NFAT to stimulate transcription of hypertrophic genes including Rcan1.4 and miR-223, linking Erk1/2 and calcineurin/NFAT signaling pathways.\",\n      \"method\": \"Cardiomyocyte-specific Ets2 conditional knockout mice, calcineurin transgenic mouse model with ETS2 silencing, ChIP for ETS2 and NFAT at target promoters, co-immunoprecipitation of ETS2-NFAT complex, miR-223 functional studies\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo conditional KO, direct complex identification by co-IP and ChIP, and multiple genetic model validation\",\n      \"pmids\": [\"33821668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ETS2 is the causal gene at the chr21q22 inflammatory disease risk locus; overexpressing ETS2 in resting macrophages reproduces the inflammatory state of chr21q22-associated diseases, including upregulation of TNF and IL-23; functional genomics in primary human macrophages identified ETS2 as a central regulator of human inflammatory macrophage gene expression.\",\n      \"method\": \"Functional genomics in primary human macrophages, ETS2 overexpression, gene expression profiling, cellular signature database screening, pharmacological validation in vitro and ex vivo\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — primary human cell gain-of-function with genome-wide gene expression and pharmacological validation, high-citation foundational study\",\n      \"pmids\": [\"38839969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"ETS2 transactivates the CDC2 promoter through Ets-binding sites in its 5' flanking region; constitutive ETS2 expression in fibroblasts increases CDC2 expression, histone H1 kinase activity, and cyclin A levels, demonstrating a direct role for ETS2 in regulating G2/M cell cycle entry.\",\n      \"method\": \"Promoter-reporter transactivation assays, site-directed mutagenesis of EBS in cdc2 promoter, stable ETS2 expression in BALB/c3T3 cells, kinase activity assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter mutagenesis plus functional kinase activity assays in cells stably expressing ETS2\",\n      \"pmids\": [\"7867724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Constitutive expression of ETS2 in M1D+ myeloblast leukemia cells is sufficient to drive macrophage differentiation; ETS2 directly activates the junB promoter through Ets-binding sites, and dominant-negative ETS2 reduces junB transcription.\",\n      \"method\": \"Stable ETS2 expression in M1D+ cells, differentiation marker analysis (lysozyme, TNF-α), transient reporter assays with junB promoter, dominant-negative ETS2 transfection\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with promoter-level mechanism identified\",\n      \"pmids\": [\"8943340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ETS2 transactivates the beta-APP gene promoter via specific Ets-binding sites and cooperates with AP1; ETS2 transgenic mouse brains and fibroblasts overexpressing ETS2 show elevated beta-APP, increased presenilin-1, and increased beta-amyloid production.\",\n      \"method\": \"Reporter transactivation assays, EBS mutagenesis, ETS2 transgenic mouse brain analysis, Western blot for APP/presenilin-1/beta-amyloid\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter mechanism defined and confirmed in vivo in transgenic mouse model\",\n      \"pmids\": [\"12890557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ETS2 suppresses inflammatory cytokine production (IL-6, TNF-α, IFN-β) in macrophages by inhibiting ERK1/2, JNK, p38, and p65 MAPK/NF-κB signaling pathways, and also directly binds to and represses the IL-6 promoter; Ets2-deficient mice show exacerbated inflammation and increased susceptibility to CLP-induced sepsis.\",\n      \"method\": \"ETS2 knockdown and knockout macrophages, Ets2 conditional KO mice, CLP sepsis model, ChIP for ETS2 at IL-6 promoter, cytokine measurements, signaling pathway phosphorylation analysis\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO model with multiple molecular mechanisms and direct promoter binding by ChIP\",\n      \"pmids\": [\"31785145\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ETS2 is a sequence-specific transcriptional activator and repressor that functions as a nuclear effector of Ras/ERK/MAPK signaling: ERK1/2 directly phosphorylates a conserved N-terminal threonine (T72) in the Pointed domain region, which enhances transactivation by recruiting CBP/p300 coactivators and, in a phosphorylation-dependent manner, enables interaction with BRG1/SWI-SNF for transcriptional repression; ETS2 regulates invasion-associated proteases (MMPs, uPA), inflammatory cytokines (TNF, IL-6, miR-155), survival genes (Bcl-xL), and developmental programs (trophoblast/cardiac/hematopoietic) through direct binding to GGAA-containing Ets-binding sites, and can switch between oncogenic and tumor-suppressive functions depending on cellular ZMYND11 levels and competition with ETS1.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ETS2 is a sequence-specific transcription factor that integrates Ras/ERK/MAPK signaling with chromatin remodeling to control inflammatory, developmental, and cell-cycle gene programs. ERK1/2 phosphorylates ETS2 at a conserved N-terminal threonine (T72) within the Pointed domain, which promotes recruitment of CBP/p300 coactivators for transactivation and, context-dependently, BRG1/SWI-SNF for transcriptional repression; an autoinhibitory C-terminal domain additionally modulates DNA-binding affinity [PMID:9710599, PMID:15572696, PMID:12637547, PMID:1409581]. ETS2 directly activates invasion-associated proteases (MMP-9, MMP-3, uPA), inflammatory mediators (TNF, IL-6, miR-155, chemokines), survival genes (Bcl-xL), and developmental regulators (CDX2 in trophoblast stem cells, hypertrophic genes with NFAT in cardiomyocytes), and its phosphorylation-site knock-in (T72A) mice develop normally but show impaired mammary tumor progression and attenuated macrophage inflammatory responses [PMID:9573048, PMID:14612405, PMID:24362029, PMID:33821668, PMID:27659014]. ETS2 is the causal gene at the chr21q22 inflammatory disease risk locus, where its overexpression in human macrophages is sufficient to reproduce the inflammatory transcriptional signature of associated diseases [PMID:38839969].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Establishing that ETS2 is an unstable nuclear phosphoprotein whose abundance is post-translationally controlled answered how ETS2 levels can be acutely regulated without transcriptional changes.\",\n      \"evidence\": \"Pulse-chase metabolic labeling and PKC activator treatment in cultured cells\",\n      \"pmids\": [\"3062367\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the E3 ligase/degradation pathway unknown\", \"Phosphorylation sites mediating stabilization uncharacterized\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Demonstrating that ETS2 is a sequence-specific transcriptional activator binding GGAA-containing Ets-binding sites, with rapid induction in macrophages and a role in Xenopus meiotic maturation, established ETS2 as a signal-responsive transcription factor functioning in both immune and developmental contexts.\",\n      \"evidence\": \"Gel-shift assays and reporter transactivation (HTLV-1 LTR); antisense oligonucleotide injection in Xenopus oocytes; Northern blots in macrophages stimulated with CSF, LPS, and PKC activators\",\n      \"pmids\": [\"2209540\", \"2255913\", \"2186967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream kinase cascade not yet defined\", \"Endogenous mammalian target genes unknown\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Identification of a C-terminal autoinhibitory domain that reduces DNA-binding 20–50-fold, and demonstration that the ETS2 DNA-binding domain acts as a dominant-negative blocking Ras-responsive transcription and CSF-1-dependent colony formation, placed ETS2 downstream of Ras in mitogenic signaling and revealed an intrinsic regulatory mechanism.\",\n      \"evidence\": \"Deletion mutagenesis with gel-shift assays; dominant-negative ETS2 in NIH 3T3 colony formation with epistasis rescue by c-Myc\",\n      \"pmids\": [\"1409581\", \"1448070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the kinase phosphorylating ETS2 in response to Ras not yet determined\", \"Structural basis of autoinhibition unclear\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Mapping the Ras-responsive phosphorylation to threonine-72 and showing this residue is required for transcriptional superactivation identified the key post-translational switch coupling MAPK signaling to ETS2 output; concurrently, ETS2 was shown to drive macrophage differentiation and directly activate junB.\",\n      \"evidence\": \"Phosphoamino acid analysis, T72A mutagenesis, reporter assays in NIH 3T3/RAW264; stable ETS2 expression in M1D+ myeloblasts with differentiation markers\",\n      \"pmids\": [\"8552081\", \"8943340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase performing T72 phosphorylation not yet demonstrated\", \"Coactivator mechanism downstream of pT72 unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"ERK1/2 were identified as the direct T72 kinases, and phosphorylation was linked to activation of invasion-associated protease genes (uPA, MMP-9) through composite Ets-AP-1 sites; ETS2 knockout revealed embryonic lethality from trophoblast failure with defective MMP expression, establishing essential developmental and protease-regulatory roles.\",\n      \"evidence\": \"In vitro kinase assays with recombinant ERK1/2 and ETS2, phospho-T72 antibody, MEK inhibitor PD98059; Ets2 gene-targeted knockout mice rescued by tetraploid aggregation; promoter mutagenesis of uPA/MMP-9 reporters\",\n      \"pmids\": [\"9710599\", \"9639404\", \"9573048\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ETS2 recruits coactivators upon phosphorylation not resolved\", \"Role of ETS2 in adult tissues beyond placenta unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery that phosphorylated ETS2 physically recruits CBP/p300 coactivators through two independent binding regions established the coactivator-recruitment mechanism by which MAPK-phosphorylated ETS2 enhances transcription.\",\n      \"evidence\": \"Co-immunoprecipitation, GST-pulldown with purified proteins, domain-mapping deletions, stromelysin reporter assays\",\n      \"pmids\": [\"10358095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether phosphorylation is strictly required for CBP/p300 interaction not fully demonstrated here\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"ETS2 was shown to synergize with PU.1 to activate Bcl-xL transcription and promote macrophage survival, and CDK10 was identified as a Pointed-domain-specific interactor that inhibits ETS2 transactivation, revealing both a pro-survival target gene and a negative regulatory partner.\",\n      \"evidence\": \"Reporter assays and domain deletions for ETS2-PU.1 synergy on Bcl-xL promoter; CSF-1 withdrawal survival assays; yeast two-hybrid and co-IP for CDK10-ETS2 interaction\",\n      \"pmids\": [\"11278399\", \"11313931\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological conditions under which CDK10 inhibits ETS2 unclear\", \"Kinase activity of CDK10 toward ETS2 not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The Pointed domain was found to recruit the BRG1/SWI-SNF complex in a phosphorylation-dependent manner for transcriptional repression (e.g., BRCA1), and ETS2 overexpression was shown to induce p53-dependent apoptosis, revealing dual activator-repressor functionality and a link to the p53 pathway.\",\n      \"evidence\": \"Affinity purification of Pointed-domain interactors, co-IP/pulldown for BRG1, BRCA1 reporter repression; ETS2 transgenic mice crossed with p53-null mice for genetic rescue of thymic apoptosis\",\n      \"pmids\": [\"12637547\", \"12554679\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ETS2 switches between CBP/p300 activation and BRG1-mediated repression at specific loci unclear\", \"Mechanism by which ETS2 induces p53 not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstration that ETS2 T72A knock-in mice develop normally but show restricted mammary tumor growth with decreased stromal MMP expression established that MAPK-mediated ETS2 phosphorylation is dispensable for development but critical for tumor microenvironment function.\",\n      \"evidence\": \"T72A knock-in mice in multiple mammary tumor models (PyMT, Neu); macrophage MMP-9/MMP-3 analysis from tumor stroma\",\n      \"pmids\": [\"14612405\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether T72A affects all ETS2-dependent inflammatory programs not tested\", \"Cell-autonomous versus stromal contributions not fully separated\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Unbiased affinity chromatography confirmed that phospho-T72 preferentially recruits CBP/p300 in HeLa nuclear extracts, and the T72A knock-in was shown to reduce inflammatory macrophage gene expression and extend lifespan in a chronic inflammation model, unifying the phosphorylation-coactivator mechanism with in vivo inflammatory outcomes.\",\n      \"evidence\": \"Phospho-ETS2 affinity chromatography of HeLa nuclear extracts; Ets2A72 × Hcph me-v double mutant mice with macrophage gene expression and survival analysis\",\n      \"pmids\": [\"15572696\", \"15240733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide identification of phospho-ETS2-dependent target genes not performed\", \"PTEN-mediated suppression of ETS2 phosphorylation not tested in vivo\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Conditional ETS2 knockout in trophoblast stem cells revealed that ETS2 maintains TS cell self-renewal through direct regulation of CDX2, a master trophoblast transcription factor, extending its developmental role beyond placental tissue structure to stem cell identity.\",\n      \"evidence\": \"Conditional Ets2 knockout in TS cells, gene expression and chromatin analysis for CDX2 as direct target\",\n      \"pmids\": [\"17977525\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Full set of ETS2-regulated stem cell genes not defined\", \"Mechanism of ETS2 regulation of CDX2 (enhancer architecture) not detailed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"ETS2 was found to mediate gain-of-function mutant p53 binding to ETS-binding sites genome-wide, activating TDP2 to confer etoposide resistance; separately, co-expression of ETS2 with MESP1 was sufficient to reprogram fibroblasts into cardiac progenitors, revealing a new oncogenic partnership and a cardiogenic function.\",\n      \"evidence\": \"ChIP-seq for mutant p53, co-IP with ETS2, TDP2 knockdown sensitization; lentiviral ETS2+MESP1 expression with cardiac marker and functional readouts in human fibroblasts\",\n      \"pmids\": [\"22508727\", \"22826236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ETS2-mutant p53 axis operates across all p53 mutation types unknown\", \"In vivo cardiac reprogramming with ETS2+MESP1 not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"ETS2 was shown to directly activate miR-155 transcription in LPS-stimulated macrophages and to interact with the MLL histone methyltransferase complex to activate MMP1/MMP3 through H3K4me3 deposition, linking ETS2 to both microRNA regulation and epigenetic gene activation at invasion-related loci.\",\n      \"evidence\": \"ChIP for ETS2 at miR-155 promoter with Ets2-deficient mice; co-IP of ETS2-MLL complex, ChIP for H3K4me3 at MMP promoters upon HGF treatment\",\n      \"pmids\": [\"24362029\", \"23934123\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Global landscape of ETS2-MLL co-regulated genes undefined\", \"Whether ETS2-MLL interaction is phosphorylation-dependent not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"ZMYND11 was identified as a co-repressor that attenuates ETS2 transcriptional output relative to ETS1, with ZMYND11 expression levels determining whether ETS2 acts as oncogene or tumor suppressor; separately, ETS2 was found to drive snoRNA expression and metastatic phenotype in p53-mutant osteosarcomas.\",\n      \"evidence\": \"ChIP-seq cistrome comparison of ETS1/ETS2, ZMYND11 interaction mapping and transcriptional assays; RNA-seq of p53-mutant osteosarcomas with conditional ETS2 deletion\",\n      \"pmids\": [\"28119415\", \"29021240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ZMYND11-ETS2 selectivity over ETS1 unknown\", \"Mechanism connecting snoRNAs to metastasis not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"ETS2 was shown to function as an anti-inflammatory regulator by directly repressing the IL-6 promoter and inhibiting MAPK/NF-κB signaling in macrophages, with Ets2-deficient mice showing exacerbated sepsis, demonstrating context-dependent activator versus repressor roles in inflammation.\",\n      \"evidence\": \"ChIP for ETS2 at IL-6 promoter, conditional ETS2 KO mice in CLP sepsis model, signaling pathway phosphorylation analysis\",\n      \"pmids\": [\"31785145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ETS2 switches from inflammatory gene activator to repressor at specific promoters not mechanistically resolved\", \"Discrepancy with pro-inflammatory ETS2 functions at other loci needs reconciliation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"In cardiomyocytes, ERK1/2-phosphorylated ETS2 was shown to form a complex with NFAT to co-activate hypertrophic genes including Rcan1.4 and miR-223, and cardiomyocyte-specific ETS2 knockout protected from pressure overload-induced hypertrophy, establishing ETS2 as an integrator of ERK and calcineurin/NFAT signaling in cardiac disease.\",\n      \"evidence\": \"Cardiomyocyte-specific Ets2 conditional KO mice with pressure overload, co-IP of ETS2-NFAT, ChIP at Rcan1.4 and miR-223 promoters\",\n      \"pmids\": [\"33821668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full cardiac ETS2 targetome not defined\", \"Whether pT72 is specifically required in cardiac hypertrophy not tested with knock-in\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"ETS2 was identified as the causal gene at the chr21q22 inflammatory disease risk locus; overexpression in primary human macrophages recapitulated the inflammatory transcriptional signature, establishing ETS2 as a master regulator of human inflammatory macrophage identity.\",\n      \"evidence\": \"Functional genomics in primary human macrophages, ETS2 overexpression with genome-wide gene expression profiling, pharmacological validation\",\n      \"pmids\": [\"38839969\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic targeting strategies for ETS2 in inflammatory bowel disease not yet clinically validated\", \"Whether ZMYND11 modulates disease-associated ETS2 activity not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The mechanism by which ETS2 switches between transcriptional activation (via CBP/p300) and repression (via BRG1/SWI-SNF or ZMYND11) at specific genomic loci, and how this switching is dysregulated in disease, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of the ETS2 Pointed domain in complex with its diverse co-regulators\", \"Genome-wide maps of ETS2 activator vs. repressor modes not available\", \"Pharmacological approaches to selectively modulate ETS2 activity lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 6, 9, 24, 28]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 7, 9, 10, 11, 13, 14, 16, 22, 24, 30, 32, 36]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 8, 17, 31]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 11, 13, 14, 22, 24, 26, 30, 32]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [19, 24, 27, 28, 32, 36]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 10, 21, 23]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [15, 16, 20]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [33]}\n    ],\n    \"complexes\": [\n      \"SWI/SNF (BRG1/BAF57/INI1)\",\n      \"MLL histone methyltransferase complex\"\n    ],\n    \"partners\": [\n      \"CBP\",\n      \"EP300\",\n      \"BRG1\",\n      \"ZMYND11\",\n      \"NFAT\",\n      \"PU.1\",\n      \"CDK10\",\n      \"TP53\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}